Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on November 12, 2019. The filing serves to announce the company's financial results for the quarter ended September 30, 2019. The registrant is classified as an emerging growth company.
Financial Metrics
This Form 8-K does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the full text of the press release containing these results is furnished as Exhibit 99.1 and incorporated by reference. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body of the report. Investors must refer to the referenced press release (Exhibit 99.1) for comparative analysis of the quarter ended September 30, 2019.
Guidance, Outlook, and Risks
The document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report notes that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its liability scope compared to standard periodic reports.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended September 30, 2019, by reviewing Exhibit 99.1 (Press Release) attached to this filing.
- Confirm the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Note that the financial data in this 8-K is not directly presented in the text but is incorporated by reference from an external press release.